Trials / Completed
CompletedNCT02878122
Study of Predictive Factors of Chemoresistance in Ovarian Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 13 (actual)
- Sponsor
- Rennes University Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Cancer treatment | Chemotherapy and laparoscopic surgery |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2020-03-01
- Completion
- 2020-03-01
- First posted
- 2016-08-25
- Last updated
- 2021-08-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02878122. Inclusion in this directory is not an endorsement.